How Much Does Wegovy Cost in Vermont in 2026?

Vermont Retail Pricing for Wegovy

The wholesale acquisition cost (WAC) set by Novo Nordisk for Wegovy is $1,349 per month. That figure represents the manufacturer list price before any insurance negotiation or pharmacy discount. Vermont retail pharmacies, including chains such as CVS, Walgreens, and Kinney Drugs, generally charge close to this list price for cash-pay customers in 2026.

Price does not vary by dose during the escalation phase. A patient filling the 0.25 mg starter pen pays the same monthly cost as someone on the maintenance dose of 2.4 mg, because each carton contains four pre-filled pens covering one month of once-weekly injections. Some pharmacies offer modest cash-pay discounts through GoodRx or similar aggregators, but savings rarely exceed 5 to 10% off list price without insurance or a manufacturer program.

Vermont has no state-level drug price cap that applies to Wegovy specifically. The state's prescription drug affordability board, established under Act 165 (2022), reviews high-cost drugs but has not issued an upper payment limit for semaglutide 2.4 mg as of May 2026. Patients paying full retail should compare prices across independent and chain pharmacies, because markups differ.

Vermont Medicaid Coverage

Vermont Medicaid covers Wegovy with prior authorization. The Green Mountain Care plan requires prescribers to document that the patient has a BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. The prior authorization request must also confirm that the patient has attempted lifestyle modification (diet and exercise) for at least 6 months before starting pharmacotherapy.

Vermont expanded Medicaid anti-obesity medication (AOM) access in 2024, making it one of the states where Medicaid beneficiaries can obtain GLP-1 receptor agonists for chronic weight management rather than only for diabetes. Coverage approval typically takes 5 to 10 business days. Denials can be appealed through the standard fair hearing process.

Once authorized, Medicaid beneficiaries pay little to no copay. The exact copay depends on whether the patient falls into the standard or expanded eligibility group, but Vermont Medicaid copays for preferred branded drugs are generally $1 to $3 per fill. Wegovy's placement on the Vermont Medicaid preferred drug list (PDL) is subject to supplemental rebate negotiations between the state and Novo Nordisk, so formulary status can shift at the start of each fiscal year.

Commercial Insurance Coverage in Vermont

Coverage for Wegovy among Vermont commercial insurers is inconsistent. Blue Cross Blue Shield of Vermont (BCBSVT), MVP Health Care, and Cigna all operate plans in the state, and each sets its own formulary rules for anti-obesity medications.

BCBSVT added Wegovy to select employer-sponsored plans in late 2024, but individual marketplace plans under the Vermont Health Connect exchange may exclude weight-management drugs entirely. MVP Health Care covers Wegovy on some group plans with a step-therapy requirement: patients must first try (and fail) a lower-cost AOM such as phentermine or naltrexone-bupropion (Contrave) before Wegovy is authorized.

The Affordable Care Act does not mandate coverage of anti-obesity medications. That gap means Vermont insurers can legally exclude Wegovy from their formularies even if they cover other GLP-1 drugs like Ozempic for diabetes. Patients should call the number on the back of their insurance card and ask two specific questions: (1) Is semaglutide 2.4 mg (Wegovy) on my formulary for obesity? (2) What prior authorization or step-therapy criteria apply?

Out-of-pocket costs for commercially insured patients who do have coverage range from $25 to $500 per month, depending on the plan's specialty-tier copay or coinsurance structure. A 2023 analysis in JAMA Network Open found that high cost-sharing for AOMs reduced medication adherence by 40% within the first year, a pattern that likely applies in Vermont as well.

The Novo Nordisk Savings Card

Novo Nordisk offers a manufacturer savings card for Wegovy that can reduce the out-of-pocket cost to as little as $0 per month for eligible patients. The card applies to patients with commercial insurance whose plan covers Wegovy but imposes a copay or coinsurance.

Key eligibility rules: the patient must have commercial (private) insurance, the plan must cover Wegovy at some level, and the patient cannot be enrolled in a government-funded program (Medicare, Medicaid, Tricare, VA). The savings card covers up to $500 per 28-day fill, with a maximum annual benefit that Novo Nordisk adjusts periodically. As of early 2026, the annual cap is $3,600.

Vermont patients should be aware that the savings card does not reduce the plan's negotiated price. It offsets the patient's share only. If a plan does not cover Wegovy at all, the savings card does not apply. Patients can check eligibility and download the card at the Novo Nordisk patient assistance website or ask their prescribing provider's office to enroll them.

For uninsured Vermont patients, Novo Nordisk also operates the Wegovy Patient Assistance Program (PAP), which provides the medication at no cost to qualifying individuals whose household income falls below 400% of the federal poverty level. The application requires income documentation and a prescription from a licensed provider.

Compounded Semaglutide 2.4 mg in Vermont

Compounded semaglutide 2.4 mg is available in Vermont through licensed 503A compounding pharmacies. These pharmacies can legally compound semaglutide when they hold a valid state license and operate under a patient-specific prescription, per FDA guidance on 503A compounding. The typical cost is approximately $199 per month, a fraction of the $1,349 brand-name price.

Vermont's Board of Pharmacy regulates 503A compounding pharmacies under 26 V.S.A. Chapter 36. Pharmacies must compound from bulk drug substance that meets USP grade standards, and each preparation must be dispensed pursuant to a valid prescription for an identified individual patient.

Several points deserve attention. Compounded semaglutide is not FDA-approved. It has not undergone the same bioequivalence testing as Wegovy. The FDA issued a safety alert in 2024 warning that some compounded semaglutide products used semaglutide salt forms (such as semaglutide sodium) that differ from the base form in Wegovy, potentially altering potency and dose accuracy.

Patients considering compounded semaglutide should verify that the pharmacy is licensed in Vermont, ask whether the product uses semaglutide base (not a salt form), and confirm that sterility testing is performed on each batch. Dr. Robert Kushner, a professor of medicine at Northwestern University Feinberg School of Medicine, has noted: "Patients need to understand that compounded GLP-1 products do not carry the same regulatory oversight as FDA-approved formulations, and that purity and potency can vary between batches."

Compounded semaglutide remains a lower-cost option for Vermont patients who cannot afford Wegovy's list price and do not have insurance coverage. The cost difference ($199 vs. $1,349) is substantial enough that many patients accept the trade-off, but the decision should involve a candid conversation with a prescriber about risks and quality assurance.

Telehealth Access in Vermont

Vermont permits telehealth prescribing of Wegovy. State law (Act 6 of 2020, extended by subsequent legislation) allows prescribers to conduct initial evaluations and write prescriptions for scheduled and non-scheduled medications via audio-video telemedicine platforms. Semaglutide 2.4 mg is not a controlled substance, so no in-person visit is required before prescribing.

Several national telehealth platforms serve Vermont patients for GLP-1 prescriptions. HealthRX, Ro, Calibrate, and Found all operate in the state. Consultation fees range from $49 to $199 for the initial visit, with monthly or quarterly follow-ups included in some programs.

Telehealth visits for Wegovy typically include: a medical history review, BMI calculation, screening for contraindications (personal or family history of medullary thyroid carcinoma, MEN2 syndrome, or pancreatitis), and a discussion of dose escalation. Vermont-licensed providers can send prescriptions to any Vermont retail or mail-order pharmacy.

A practical advantage for Vermont patients in rural areas, including the Northeast Kingdom and parts of southern Vermont where obesity-medicine specialists are scarce, is that telehealth eliminates the 60-to-90-minute drive to Burlington or Montpelier for a weight-management consultation. The CDC reports that Vermont's adult obesity rate reached 29.1% in 2023, underscoring the clinical need for accessible prescribing pathways across the state.

Clinical Evidence Behind Wegovy

Wegovy's efficacy is grounded in the STEP clinical trial program. In STEP-1 (N=1,961), adults with obesity (BMI ≥30) or overweight (BMI ≥27 with a comorbidity) who received semaglutide 2.4 mg once weekly achieved a mean weight loss of 14.9% of body weight at 68 weeks, compared with 2.4% in the placebo group. That 12.5 percentage-point difference was statistically significant (P<0.0001).

STEP-3 added intensive behavioral therapy to the regimen and showed 16.0% mean weight loss at 68 weeks with semaglutide versus 5.7% with placebo. STEP-4 demonstrated that discontinuing semaglutide after 20 weeks of treatment led to a regain of approximately two-thirds of the lost weight by week 68, reinforcing that ongoing treatment is necessary to maintain results.

SELECT (N=17,604), published in The New England Journal of Medicine in 2023, found that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (MACE) by 20% in adults with overweight or obesity and established cardiovascular disease. That trial led to Wegovy's supplemental FDA approval for cardiovascular risk reduction in March 2024.

The American Association of Clinical Endocrinology (AACE) 2023 obesity treatment algorithm positions GLP-1 receptor agonists as first-line pharmacotherapy for patients with a BMI ≥30 or a BMI ≥27 with complications, after or alongside lifestyle modification.

Common side effects include nausea (reported in 44% of STEP-1 participants on semaglutide vs. 18% on placebo), diarrhea (30% vs. 16%), vomiting (24% vs. 6%), and constipation (24% vs. 11%). Most gastrointestinal symptoms are mild to moderate and peak during dose escalation. The Wegovy prescribing information carries a boxed warning about thyroid C-cell tumors based on rodent data, though no causal link has been established in humans.

Cost-Reduction Strategies for Vermont Patients

Several approaches can bring the effective monthly cost of Wegovy below $1,349 for Vermont residents.

Insurance-based paths. If your commercial plan covers Wegovy, combine plan coverage with the Novo Nordisk savings card to reduce your copay to $0 to $25 per month. If your plan denies coverage, ask your prescriber to submit a peer-to-peer review or a formal appeal citing the STEP-1 data and the AACE guideline recommendation.

Medicaid. Vermont Medicaid covers Wegovy with PA. Work with your prescriber to document the required BMI threshold, comorbidities, and prior lifestyle modification. Expect a 5-to-10-day turnaround.

Patient assistance. The Novo Nordisk PAP covers Wegovy at $0 for uninsured patients below 400% FPL. Apply through your provider's office.

Compounded semaglutide. At roughly $199 per month from a licensed 503A pharmacy, this is the lowest-cost semaglutide option. Confirm the pharmacy's Vermont license, the semaglutide form (base, not salt), and batch sterility testing.

Mail-order pharmacy. Some pharmacy benefit managers offer lower copays for 90-day mail-order fills versus 30-day retail fills. Check with your plan.

The Endocrine Society's 2024 clinical practice guideline on pharmacological treatment of obesity recommends that clinicians "actively assist patients in navigating insurance coverage and financial barriers to anti-obesity medications," recognizing that cost is the single largest driver of treatment discontinuation.

What to Expect During Dose Escalation

Wegovy uses a 16-week dose escalation schedule to reduce gastrointestinal side effects. The protocol: 0.25 mg weekly for weeks 1 through 4, 0.5 mg for weeks 5 through 8, 1.0 mg for weeks 9 through 12, 1.7 mg for weeks 13 through 16, and 2.4 mg (maintenance) from week 17 onward.

Each dose step requires a new prescription fill. Vermont patients using insurance should confirm that their plan authorizes all five dose strengths at the outset, rather than requiring separate prior authorizations at each step. Some plans have tripped up patients by approving the starter dose but denying the maintenance dose.

Weight loss during escalation is modest. Most of the clinically significant loss occurs after reaching the 1.7 mg or 2.4 mg dose. In STEP-1, the weight-loss curve continued to slope downward through week 60 before plateauing. Patients who do not tolerate the full 2.4 mg dose can, in consultation with their prescriber, remain at 1.7 mg, though the FDA label specifies 2.4 mg as the recommended maintenance dose.

Patients should inject Wegovy subcutaneously in the abdomen, thigh, or upper arm, rotating sites weekly to reduce injection-site reactions. Store unused pens in the refrigerator (36 to 46°F). An in-use pen can remain at room temperature (up to 86°F) for up to 28 days.